〔Abstract〕Objective To investigate the clinical effect of sacubitril valsartan sodium combined with metoprolol succinate sustained release tablets in the treatment of heart failure after acute myocardial infarction. Methods A total of 80 patients with acute myocardial infarction complicating heart failure admitted to the 7th People's Hospital of Zhengzhou from January 2018 to January 2019, and divided into a control group and an observation group, with 40 cases in each group. The control group was received conventional drug treatment,the observation group was on the basis of the control group conventional treatment, and the enalapril maleate tablets was replaced with sacubitril valsartan sodium. After 6 months of treatment, the clinical effect, the improvement of heart function index of left ventricular ejection fraction (LVEF) and N terminal b-type natriuretic peptide (NT-proBNP) of the two groups were compared. Results The total effective rate of the observation group was 90%, higher than 72.5% of the control group, and the difference was statistically significant (P < 0.05); After 6 months of follow-up, LVEF and 6 min walking distance (6MWT) in the observation group were significantly higher than those in the control group, and the level of NT-proBNP was significantly lower than that in the control group, with statistically significant differences (P < 0.05). Conclusion Application of sacubitril valsartan sodium combined with metoprolol succinate sustained release tablets in the treatment of heart failure after acute myocardial infarction can improve cardiac function, exercise endurance and quality of life.